(Adnkronos) - “Gli studi dei trial clinici sull'impiego del mepolizumab nei pazienti con asma grave hanno confermato, sin dalle prime somministrazioni, l'efficacia del farmaco nella riduzione netta delle riacutizzazioni. Lo studio di real life ha confermato, nei 2 anni di osservazione, anche il mantenimento di questo miglioramento in termini di qualità di vita e dei parametri clinici e biologici analizzati”. Lo ha detto all’Adnkronos Salute Nicola Scichilone, direttore della Pneumologia del policlinico P. Giaccone di Palermo, a Milano nella seconda giornata del XXV congresso nazionale della Società italiana di pneumologia (Sip), in occasione del simposio Gsk sulle malattie eosinofile e l’evoluzione dell’approccio terapeutico dell’anticorpo monoclonale mepolizumab.
Category
🗞
NewsTranscript
00:00There is no doubt that the advent of biological therapies for monoclonal antibodies has revolutionized
00:12the management of serious asthma.
00:14The goal declared from the beginning was to reduce the use of steroids for systemic reasons
00:22until complete suspension, and we can say that biological therapies have allowed us to achieve this goal,
00:31as well as the reduction of the frequency of re-acutization and the control of symptoms.
00:39Today we are quite confident that with biological therapies we can achieve clinical remission in a good number of patients.
00:50The real challenge is to maintain clinical remission over the years, and the initial data tell us that this is possible
00:57at least in the three years of observation, but we can also aim at biological remission,
01:03which, by extinguishing inflammation, can have an impact on the natural history of the disease,
01:09on the progression of the disease, therefore essentially modifying the disease itself.
01:15The clinical trials with the use of mepolizumab in patients with serious asthma
01:24have confirmed the effectiveness of the drug in the clear reduction,
01:30since the first supply of re-acutization, on the control of symptoms and on the improvement.
01:37The confirmation was made by the studies of Real Life.
01:41The Reality AI is certainly the study that has confirmed, in the two years of observation,
01:48not only the improvement since the initial phases, but also the maintenance of this gain in terms of quality of life
01:57and the clinical and biological parameters that have been analyzed.
02:01The future is to evaluate in a longer period of time the maintenance of clinical remission.
02:10The data are encouraging in this sense, but also the clinical experience that anyone who works on the field
02:19knows that it can hold and know that it can count on an effective drug like antithelioquine 5 and mepolizumab.